Acta Crystallographica Section E

Structure Reports Online

ISSN 1600-5368

Abdullah Aydın, ^a Tijen Önkol, ^b Mehmet Akkurt, ^{c*} Orhan Büyükgüngör ^d and Serdar Ünlü^b

^aDepartment of Physics Education, Kastamonu Education Faculty, Gazi University, 37200 Kastamonu, Turkey, ^bDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Etiler, 06330 Ankara, Turkey, ^cDepartment of Physics, Faculty of Arts and Sciences, Erciyes University, 38039 Kayseri, Turkey, and ^dDepartment of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, 55139 Kurupelit–Samsun, Turkey

Correspondence e-mail: aaydin@gazi.edu.tr

Key indicators

Single-crystal X-ray study T = 293 KMean $\sigma(C-C) = 0.003 \text{ Å}$ Disorder in main residue R factor = 0.033 wR factor = 0.085 Data-to-parameter ratio = 15.6

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

3-(6-Benzoyl-5-chloro-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid

The title compound, $C_{17}H_{12}CINO_5$, consists of a main benzothiazole group and its substituents which are one Cl atom, a benzoyl group and a propanoic acid group. There is a 0.779 (4)/0.221 (4) disorder in the terminal propanoic acid group. The crystal structure is stabilized by intermolecular $O-H\cdots O$ hydrogen-bond contacts.

Received 12 January 2004 Accepted 28 January 2004 Online 7 February 2004

Comment

The title compound, (I), shows analgesic activity comparable to aspirin, and results in lower anti-inflammatory activity than that of indometacin. This compound caused gastric lesions and bleeding in the stomachs of tested animals (Fereira *et al.*, 1995; Ünlü *et al.*, 2003). We report here the structure of (I), shown in Fig. 1.

The structure of (I) exhibits disorder. Atoms C2A, C3A, C4A, O3A and O4A in the propanoic acid group and atom N1A in the benzothiazole group have a site-occupancy of 0.779 (4) versus 0.221 (4) for the minor component B of the same groups. Within experimental uncertainty, the bond lengths and angles in the disordered compound are comparable to those in related structures (Allen et al., 1987; Aydın et al., 2002).

In the disordered propanoic acid group, the average C-C bond length and the C-C-C bond angle are 1.506 (18) Å and 113.3 (9)°, respectively. These values are in agreement with those in 3-(6-benzoyl-2-oxo-2,3-dihydro-2-benzothiazol-

A view of (I), showing 30% probability displacement ellipsoids and the atom-numbering scheme. The disordered atoms of the minor component have been omitted for clarity.

© 2004 International Union of Crystallography Printed in Great Britain – all rights reserved




Figure 2 A view of the packing of (I) along the *b* axis. The minor components of the disordered atoms have been omitted for clarity.

3-yl) propanoic acid, [1.501 (1) and 110.9 (3)°; Aydın *et al.*, 2003].

The maximum deviations from the mean plane through the bicylic benzothiazole system (O1/C1/N1A/N1B/C5–C10) are -0.105 (3), 0.38 (1), 0.015 (2) and -0.016 (2) Å for atoms N1A, N1B, C6 and C8, respectively. The dihedral angle between the least-squares planes of the benzothiazole group and the phenyl ring (C12–C17) is 72.81 (5)°, and is comparable with the angle of 74.7 (1)° in 5-chloro-6-(2-fluorobenzoyl)-1,3-benzoxazol-2(3H)-one (Aydın $et\ al.$, 2004).

The crystal structure of (I) is stabilized by intermolecular $O-H\cdots O$ hydrogen-bond contacts (Table 2).

Experimental

3-(6-Benzoyl-5-chloro-2-oxo-3*H*-benzoxazol-3-yl)propionitrile (0.01 mol) was added to an *N,N*-dimethylformamide–water–sulfuric acid (1:1:2) mixture (50 ml). After stirring at room temperature for 2 h, the mixture was refluxed for 4 h. The mixture, cooled to room temperature, was poured into ice–water. The resulting precipitate was filtered off by suction filtration, washed with water, dried and crystallized from ethanol–water (yield 78%, m.p. 468–469 K). IR $\nu_{\rm max}$ cm $^{-1}$ (KBr): 3060, 1770, 1665, 1600, 1480; $^{1}{\rm H}$ NMR (DMSO- $d_{\rm 6}$): δ 12.40 (1H, s, COOH), 7.87–7.81 (4H, m, 2-oxobenzoxazol-H $^{4.7}$, benzoyl-H $^{2.6}$), 7.69 (3H, m, benzoyl-H $^{3.4,5}$), 4.21 (2H, t, N-CH₂), 2.89 (2H, t, CH₂CO) (Ünlü et al., 2003).

Crystal data

Crystat data	
$C_{17}H_{12}CINO_5$	$D_x = 1.470 \text{ Mg m}^{-3}$
$M_r = 345.73$	Mo K α radiation
Monoclinic, C2/c	Cell parameters from 6761
a = 26.015 (10) Å	reflections
b = 6.252 (5) Å	$\theta = 1.7 – 28.1^{\circ}$
c = 20.412 (4) Å	$\mu = 0.27 \text{ mm}^{-1}$
$\beta = 109.749 (16)^{\circ}$	T = 293 K
$V = 3125 (3) \text{ Å}^3$	Plate, colorless
Z = 8	$0.60 \times 0.44 \times 0.13 \text{ mm}$

Data collection

Stoe IPDS-2 diffractometer	1700 reflections with $I > 2\sigma(I)$
ω scans	$R_{\rm int} = 0.033$
Absorption correction: by	$\theta_{\rm max} = 28.1^{\circ}$
integration (Stoe & Cie, 2002)	$h = -32 \rightarrow 34$
$T_{\min} = 0.854, T_{\max} = 0.965$	$k = -8 \rightarrow 8$
6761 measured reflections	$l = -16 \to 26$
3791 independent reflections	
F	
Refinement	
Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0486P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.033$	where $P = (F_0^2 + 2F_c^2)/3$
$wR(F^2) = 0.085$	$(\Delta/\sigma)_{\rm max} < 0.001$
S = 0.72	$\Delta \rho_{\text{max}} = 0.16 \text{ e Å}^{-3}$
3791 reflections	$\Delta \rho_{\min} = -0.17 \text{ e Å}^{-3}$
243 parameters	Extinction correction: SHELXL97
2 is parameters	Extinction correction. SITEEMEST

Extinction coefficient: 0.0037 (3)

Table 1 Selected geometric parameters (Å, $^{\circ}$).

H atoms treated by a mixture of independent and constrained

refinement

selected geometric parameters (A,).							
Cl1-C7	1.731 (2)	O5-C11	1.206 (3)				
O1-C1	1.374 (3)	N1A-C2A	1.453 (4)				
O1-C10	1.379(2)	N1A-C1	1.363 (3)				
O2-C1	1.195 (3)	N1A-C5	1.381 (3)				
O3A - C4A	1.220 (5)	N1B-C1	1.377 (10)				
O3B-C4B	1.24(2)	N1B-C5	1.452 (10)				
O4A - C4A	1.294 (5)	N1B-C2B	1.450 (14)				
O4B-C4B	1.22 (2)						
C1-O1-C10	107.35 (13)	O3A - C4A - O4A	123.2 (3)				
C1-N1A-C5	109.2(2)	O3A - C4A - C3A	121.9(3)				
C1-N1A-C2A	123.3 (2)	O4B-C4B-C3B	114.9 (11)				
C2A-N1A-C5	127.2(2)	O3B-C4B-O4B	128.2 (15)				
C1-N1B-C2B	125.1 (8)	O3B-C4B-C3B	114.3 (15)				
C1-N1B-C5	104.5 (6)	N1A-C5-C10	106.20 (16)				
C2B-N1B-C5	128.2 (8)	N1B - C5 - C10	104.5 (4)				
O1-C1-N1A	107.70 (18)	N1A - C5 - C6	132.26 (18)				
O2-C1-N1A	129.6 (2)	N1B-C5-C6	131.7 (4)				
O2-C1-N1B	127.8 (4)	Cl1-C7-C8	119.43 (13)				
O1 - C1 - O2	122.47 (17)	Cl1-C7-C6	117.58 (12)				
O1 - C1 - N1B	107.4 (5)	O1-C10-C9	128.31 (15)				
N1A-C2A-C3A	112.2 (2)	O1-C10-C5	109.05 (14)				
N1B-C2B-C3B	112.7 (8)	O5-C11-C12	121.53 (18)				
O4A - C4A - C3A	114.9 (3)	O5-C11-C8	118.83 (17)				

Table 2 Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdot \cdot \cdot A$	$D-\mathrm{H}\cdots A$
$O4A - H4A \cdot \cdot \cdot O3A^{i}$	0.82	1.81	2.622 (4)	173

Symmetry code: (i) $\frac{1}{2} - x, \frac{7}{2} - y, -z$.

The minor component B of the disordered group was restrained to have geometry similar to that of the major component. All H atoms were placed in idealized positions (C—H = 0.97 Å for methylene groups, C—H = 0.93 Å for the phenyl group and O—H = 0.82 Å for the hydroxyl group). A riding model was used in the refinement procedure. The $U_{\rm iso}$ values were constrained to be 1.2 times $U_{\rm eq}({\rm C})$ of the carrier atom for the phenyl and methylene groups, and 1.5 times $U_{\rm eq}({\rm O})$ of the carrier atom for the hydroxyl group.

Data collection: *X-AREA* (Stoe & Cie, 2002); cell refinement: *X-AREA*; data reduction: *X-RED*32 (Stoe & Cie, 2002); program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1997); program(s)

used to refine structure: *SHELXL*97 (Sheldrick, 1997); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *PLATON* (Spek, 1990) and *WinGX* publication routines (Farrugia, 1999).

The authors acknowledge the Faculty of Arts and Sciences, Ondokuz Mayıs University, Turkey, for the use of the Stoe IPDS-II diffractometer (purchased under grant F.279 of the University Research Fund).

References

Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans.* 2, pp. S1–19.

- Aydın, A., Arıcı, C., Akkurt, M., Akkoç, Y. & Şahin, M. F. (2002). Anal. Sci. 18, 1401–1402.
- Aydın, A., Önkol, T., Akkurt, M., Büyükgüngör, O. & Ünlü, S. (2004). *Acta Cryst.* E**60**, o244–o245.
- Aydın, A., Önkol, T., Arıcı, C., Akkurt, M., Şahin, M. F. & Ülkü, D. (2003).
 Acta Cryst. E59, 0616–0618.
- Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.
- Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837–838.
- Fereira, S. H., Lorenzetti, B. B., Devissaguet, M., Lesieur, D. & Tsouderos, Y. (1995). *Br. J. Pharmacol.* **114**, 303–308.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
- Spek, A. L. (1990). Acta Cryst. A46, C-34.
- Stoe & Cie (2002). X-AREA (Version 1.18) and X-RED32 (Version 1.04) Stoe & Cie, Darmstadt, Germany.
- Ünlü, S., Önkol, T., Dündar, Y., Ökçelik, B., Küpeli, E., Yeşilada, E., Noyanalpan, N. & Şahin, M. F. (2003). Arch. Pharm. Parm. Med. Chem. 336, 353–361.